Bausch + Lomb Corporation

BLCO Healthcare Medical Instruments & Supplies

Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024.

Revenue
+7.34%
EPS
+222.4%
Free cash flow
+182.5%
Total debt
+2.93%

Quarter to September 2026, against a year earlier

19.96 0.04 +0.20%
Market cap
$7.1B
P/E
0.0×
Fwd P/E
749×
Dividend yield
—
F-score
3/9
Altman Z
0.87
Beneish M
−2.52
Dividend safety
n/a

Bausch + Lomb Corporation (BLCO) P/E ratio

Alert me on P/E ratio

Bausch + Lomb Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 946× (February 2023) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 786× 1,966.00%
FY2021 38.0× 0.00%
FY2020 38.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
19 more quarters

Against its own ten years

Low 0.0× High 946×
Ten-year median 0.0×
Current reading's percentile 80

P/E ratio against peers

Company P/E ratio
RGEN Repligen Corporation compare n/m
MMED MiniMed Group, Inc. compare n/m
BLCO Bausch + Lomb Corporation n/m
TFX Teleflex Incorporated compare 18.2×
COO The Cooper Companies, Inc. compare 21.3×
ALGN Align Technology, Inc. compare 24.0×
AVTR Avantor, Inc. compare 30.8×
MMSI Merit Medical Systems, Inc. compare 32.5×
ATR AptarGroup, Inc. compare 34.1×
Medical Instruments & Supplies industry median 30.8×
Healthcare sector median 24.5×
Market median 17.8×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on BLCO